UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Annals of oncology, 2019-11, Vol.30 (11), p.1784-1795

2019

Volltextzugriff (PDF)

Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients

Cancer chemotherapy and pharmacology, 2011-12, Vol.68 (6), p.1529-1536

2011

Volltextzugriff (PDF)

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

Journal of clinical oncology, 1998-05, Vol.16 (5), p.1948-1953

1998

Volltextzugriff (PDF)

8000 ORAL Results of the GYNECO 02 Study, a FNCLCC Phase III Trial Comparing Hysterectomy Versus No Hysterectomy in Patients With a (Clinical and Radiological) Complete Response After Chemoradiation Therapy in IB2/II Stage Cervical Cancer

European journal of cancer (1990), 2011, Vol.47, p.S527-S527

2011

Volltextzugriff (PDF)

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Journal of clinical oncology, 2000-05, Vol.18 (10), p.2095-2103

2000

Volltextzugriff (PDF)

Phase i dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (dl-d2-d3) in patients with refractory solid tumors

Cancer chemotherapy and pharmacology, 2007-04, Vol.59 (5), p.689-695

2007

Volltextzugriff (PDF)

Docetaxel (taxotere®) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer

European journal of cancer (1990), 1998-12, Vol.34 (13), p.2032-2036

1998

Volltextzugriff (PDF)

Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer

Seminars in oncology, 1995-04, Vol.22 (2 Suppl 4), p.22

1995

Volltextzugriff (PDF)

A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer

European journal of cancer (1990), 2000-06, Vol.36 (9), p.1107-1112

2000

Volltextzugriff (PDF)

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2000-03, Vol.27 (3), p.145-157

2000

Volltextzugriff (PDF)

α-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel

Clinical cancer research, 2003-03, Vol.9 (3), p.1077-1082

2003

Volltextzugriff (PDF)

Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice

Lung cancer (Amsterdam, Netherlands), 2000-09, Vol.29 (3), p.205-216

2000

Volltextzugriff (PDF)

A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer

European journal of cancer (1990), 1996, Vol.32 (1), p.69-71

1996

Volltextzugriff (PDF)

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Annals of oncology, 2019-11, Vol.30 (11), p.1784

2019

Volltextzugriff (PDF)

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer

Seminars in oncology, 1999-06, Vol.26 (3 Suppl 11), p.13

1999

Volltextzugriff (PDF)

Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4098-4098

2011

Volltextzugriff (PDF)

Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4513-4513

2011

Volltextzugriff (PDF)

Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

Anti-cancer drugs, 2000-01, Vol.11 (1), p.7-13

2000

Volltextzugriff (PDF)

Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer : the Canadian experience

Investigational new drugs, 1998-01, Vol.16 (3), p.265-270

1998

Volltextzugriff (PDF)

Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: Preliminary report of a French multicentre phase II trial

European journal of cancer (1990), 1994, Vol.30 (5), p.587-590

1994

Volltextzugriff (PDF)

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer

British journal of cancer, 1994-06, Vol.69 (6), p.1136-1140

1994

Volltextzugriff (PDF)

A phase-I dose-escalation study of SR271425 administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3133-3133

2005

Volltextzugriff (PDF)

Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer

Cancer chemotherapy and pharmacology, 1994, Vol.34 (5), p.444-446

1994

Volltextzugriff (PDF)

Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer

European journal of cancer (1990), 1993, Vol.29 (2), p.288-289

1993

Volltextzugriff (PDF)

Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid

Cancer chemotherapy and pharmacology, 1991-01, Vol.28 (6), p.448-454

1991

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(57)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(27)
Aged
(25)
Middle Aged
(25)
Adult
(24)
Female
(24)
Life Sciences & Biomedicine
(23)
Male
(23)
Oncology
(23)
Science & Technology
(23)
Lung Neoplasms - Drug Therapy
(19)
Biological And Medical Sciences
(18)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(18)
Medical Sciences
(18)
Pharmacology. Drug Treatments
(16)
Antineoplastic Agents
(15)
Chemotherapy
(14)
Lung Neoplasms - Pathology
(11)
Paclitaxel - Analogs & Derivatives
(11)
Taxoids
(11)
Antineoplastic Agents - Therapeutic Use
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

8000 ORAL Results of the GYNECO 02 Study, a FNCLCC Phase III Trial Comparing Hysterectomy Versus No Hysterectomy in Patients With a (Clinical and Radiological) Complete Response After Chemoradiation Therapy in IB2/II Stage Cervical Cancer

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Phase i dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (dl-d2-d3) in patients with refractory solid tumors

Docetaxel (taxotere®) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer

Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer

A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)

α-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel

Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice

A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer

Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16

Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12)

Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer : the Canadian experience

Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: Preliminary report of a French multicentre phase II trial

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer

A phase-I dose-escalation study of SR271425 administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors

Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer

Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer

Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid

Suchergebnisse filtern